Two Sigma Advisers
RARE icon

Two Sigma Advisers’s Ultragenyx Pharmaceutical RARE Stock Holding History

Two Sigma Advisers’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-481,600
Closed -$11.1M – 1661
2025
Q4 		$11.1M Sell
481,600
-36,100
-7% -$1.19M 0.02% 504
2025
Q3 		$15.6M Sell
517,700
-342,700
-40% -$10.3M 0.03% 379
2025
Q2 		$31.3M Sell
860,400
-76,800
-8% -$2.77M 0.06% 255
2025
Q1 		$33.9M Buy
937,200
+23,700
+3% +$986K 0.08% 235
2024
Q4 		$38.4M Sell
913,500
-74,300
-8% -$3.69M 0.09% 201
2024
Q3 		$54.9M Buy
987,800
+545,600
+123% +$27.8M 0.13% 146
2024
Q2 		$18.2M Sell
442,200
-6,000
-1% -$256K 0.04% 364
2024
Q1 		$20.9M Buy
448,200
+259,300
+137% +$12.2M 0.05% 334
2023
Q4 		$9.03M Sell
188,900
-40,600
-18% -$1.57M 0.02% 569
2023
Q3 		$8.18M Sell
229,500
-261,000
-53% -$10.3M 0.02% 536
2023
Q2 		$22.6M Sell
490,500
-7,400
-1% -$343K 0.06% 282
2023
Q1 		$20M Buy
497,900
+37,200
+8% +$1.6M 0.05% 333
2022
Q4 		$21.3M Buy
460,700
+409,300
+796% +$16.1M 0.06% 317
2022
Q3 		$2.13M Buy
+51,400
New +$2.64M 0.01% 1140
2021
Q4 		– Sell
-69,400
Closed -$6.26M – 2772
2021
Q3 		$6.26M Sell
69,400
-68,500
-50% -$6.19M 0.02% 692
2021
Q2 		$13.1M Buy
137,900
+5,800
+4% +$604K 0.03% 458
2021
Q1 		$15M Buy
132,100
+72,400
+121% +$9.86M 0.04% 432
2020
Q4 		$8.26M Buy
59,700
+22,300
+60% +$2.65M 0.02% 640
2020
Q3 		$3.07M Sell
37,400
-1,900
-5% -$157K 0.01% 949
2020
Q2 		$3.07M Buy
+39,300
New +$2.6M 0.01% 999
2016
Q1 		– Sell
-91,586
Closed -$10.3M – 2118
2015
Q4 		$10.3M Sell
91,586
-66,814
-42% -$6.68M 0.06% 313
2015
Q3 		$15.4M Buy
158,400
+104,000
+191% +$11.9M 0.1% 246
2015
Q2 		$5.57M Buy
54,400
+50,300
+1,227% +$3.91M 0.04% 444
2015
Q1 		$255K Buy
+4,100
New +$228K ﹤0.01% 1645
2014
Q4 		– Sell
-9,800
Closed -$555K – 2715
2014
Q3 		$555K Buy
+9,800
New +$493K ﹤0.01% 1479

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Two Sigma Advisers's RARE Position: Q1 2026 in Review

Two Sigma Advisers sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2026, closing a stake of 481,600 shares — an estimated $11.1M sold.

Two Sigma Advisers first reported a position in RARE in Q3 2014 and held it in 25 quarters. The position peaked at $54.9M in Q3 2024. 298 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Two Sigma Advisers reported no remaining Ultragenyx Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 481,600 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $11.1M.
  • Two Sigma Advisers first reported a position in Ultragenyx Pharmaceutical in Q3 2014 and held it in 25 quarters.
  • Two Sigma Advisers's Ultragenyx Pharmaceutical position peaked at $54.9M in Q3 2024.
  • 298 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.